ERBB2 and neoplasm: ADCs, as a next generation of targeted therapies, have redefined the field of precision oncology and validated the intersectionality among subtypes including HER2-positive, HER2-low, hormone receptor-positive and -negative disease by marrying tumour-specific targeting with potent cytotoxic or immunomodulatory mechanisms to previously unimaginable levels of efficacy.